Foley & Lardner LLP
Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.
Memorial Sloan Kettering Cancer Center
A A A C A C A C C A A A A A C A A A
A61K A61K A61K C07K A61P C07K A61K C12N C07K A61P A61K A61P A61K A61K C12N A61K A61P A61K
inventional additional additional additional inventional inventional inventional additional inventional inventional inventional inventional additional inventional additional inventional inventional additional
Jedd D. Liang Taha Weiyi Stewart Peihong
Wolchok Deng Merghoub Wang Shuman Dai